Oxytocin Acetate 5mg Review

Oxytocin has occupied a central position in neuroendocrinology research for more than a century, yet the depth of its pharmacological reach continues to expand. Originally characterized as the hormone of parturition and lactation, oxytocin is now understood to modulate social cognition, reward circuitry, stress-axis reactivity, pain processing, and cardiovascular homeostasis through a single, widely expressed G-protein-coupled receptor. 1 The research interest in this nonapeptide has grown substantially over the past two decades, with investigators using synthetic oxytocin acetate preparations to probe everything from rodent social-memory circuits to in-vitro smooth-muscle pharmacology.

This review covers the 5 mg oxytocin acetate vial offered by Apollo Peptide Sciences. It is written for research professionals: clinical pharmacologists, behavioral neuroscientists, reproductive physiologists, and biochemists sourcing reference-grade material for laboratory work. All discussions of dose, route, and effect are framed by published animal or in-vitro literature; nothing in this article constitutes clinical guidance or an endorsement of human use.

Editor's Verdict

Oxytocin acetate is one of the most pharmacologically well-characterized peptides available to researchers. Its receptor has been cloned, crystallized in complex with peptide ligands, and interrogated across dozens of species. That depth of background literature is a practical advantage: results generated with a high-purity synthetic preparation can be contextualized against decades of published controls. 2

Apollo Peptide Sciences offers the compound in a 5 mg lyophilized format at a competitive price point of $35.00. For research groups running binding-affinity panels, smooth-muscle contraction bioassays, or rodent behavioral paradigms, a 5 mg vial provides a useful working quantity. The lyophilized form confers stability advantages over aqueous solutions during shipping and short-term storage, which is important for a peptide whose disulfide bridge is susceptible to reducing conditions.

The principal concern for any oxytocin acetate supply is the integrity of the Cys1-Cys6 disulfide bond and the presence of des-amino or des-Gly-NH2 degradation products that retain partial receptor activity and can confound bioassays. A conscientious certificate of analysis (CoA) from a supplier should address these specifically by high-performance liquid chromatography (HPLC) and mass spectrometry (MS). We discuss CoA expectations in detail in the Purity and Verification section below.

Specifications

What It Is, Chemistry, Origin, and Sequence Detail

Historical discovery and early characterization

Oxytocin was the first peptide hormone to be sequenced and chemically synthesized. Vincent du Vigneaud and colleagues published the structure and synthesis in 1953 and 1954, work that earned du Vigneaud the 1955 Nobel Prize in Chemistry. 3 The name derives from the Greek for "swift birth" (oxys tokos), reflecting its first-described role in promoting uterine contractions during parturition. The posterior pituitary gland releases oxytocin in pulses; however, central oxytocinergic neurons projecting to the amygdala, hippocampus, nucleus accumbens, and brainstem are entirely distinct from the peripheral hypothalamo-neurohypophyseal tract and mediate neuromodulatory functions. 1

Primary amino-acid sequence and disulfide architecture

The nine-residue sequence is: Cys(1)-Tyr(2)-Ile(3)-Gln(4)-Asn(5)-Cys(6)-Pro(7)-Leu(8)-Gly(9)-NH2. A disulfide bridge between Cys1 and Cys6 creates a six-residue ring structure with a tripeptide tail (Pro-Leu-Gly-NH2) hanging off the ring. This architecture is shared with arginine vasopressin (AVP, also nine residues, also Cys1-Cys6 disulfide), differing only at positions 3 and 8: oxytocin carries Ile(3)/Leu(8) while AVP carries Phe(3)/Arg(8). 2

This structural similarity is not merely academic. It is the molecular basis of AVP/oxytocin receptor cross-reactivity. At higher concentrations, oxytocin can activate vasopressin V1a and V1b receptors (and, weakly, V2), a pharmacological consideration when designing bioassays or interpreting in-vivo rodent data. Conversely, AVP activates OTR at elevated concentrations. Researchers designing studies that require strict OTR selectivity should include appropriate control conditions with selective antagonists such as L-368,899 or atosiban.

Synthetic production and acetate salt formation

Research-grade oxytocin acetate is produced by solid-phase peptide synthesis (SPPS), typically using Fmoc chemistry. After chain assembly and global deprotection, the linear precursor undergoes oxidative folding under controlled redox conditions (e.g., glutathione redox buffer, air oxidation at dilute concentration) to form the Cys1-Cys6 disulfide bridge. The resulting oxidized peptide is purified by reversed-phase HPLC, typically on a C18 column with acetonitrile/water gradients, yielding the trifluoroacetate (TFA) salt as the counter-ion from standard Fmoc-SPPS. 4

TFA is cytotoxic and can confound cell-based assays; suppliers offering "acetate salt" or "TFA-free" versions have exchanged the counter-ion through an additional ion-exchange or repeated lyophilization step using dilute acetic acid. The Apollo Peptide Sciences vial is described as the acetate form, which is appropriate for cellular and receptor-binding work where TFA-related artifact is a concern.

Molecular weight clarification

The free-base molecular weight of oxytocin is 1007.19 g/mol. The acetate salt adds the mass of the acetic acid counter-ion (60.05 g/mol per acetate molecule). If the peptide carries one net positive charge (protonated N-terminus or basic side chain) and one acetate counter-ion, the salt form molecular weight is approximately 1067.24 g/mol. Suppliers sometimes report purity and vial mass in terms of the free base, sometimes the acetate salt; researchers preparing molar concentration solutions should confirm which convention the supplier's CoA uses to avoid systematic concentration errors.

Mechanism of Action

Receptor identity and G-protein coupling

Oxytocin exerts its primary pharmacological effects through a single receptor subtype, the oxytocin receptor (OTR, gene symbol OXTR), a class-A G-protein-coupled receptor (GPCR) with seven transmembrane helices. Molecular cloning of the human OTR was reported by Kimura and colleagues in 1992. 5 The receptor couples predominantly to Gq/11, activating phospholipase C-beta (PLCb), which hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) to generate inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 triggers Ca2+ release from the endoplasmic reticulum, while DAG activates protein kinase C (PKC). The resulting rise in intracellular Ca2+ underpins smooth-muscle contraction in the uterus and myoepithelial cells of the mammary gland.

Additionally, OTR couples to Gi in some cell types, leading to inhibition of adenylyl cyclase and reduced cyclic AMP (cAMP) production. Context-dependent signaling through Gs (cAMP elevation) has also been reported in specific neuronal preparations, though this is less well characterized. 6 Beta-arrestin recruitment follows phosphorylation of the receptor's intracellular loops by GRK2 and GRK3, driving internalization and receptor desensitization. The relative contributions of G-protein-dependent and beta-arrestin-dependent signaling are an active area of investigation, particularly for neuronal OTR populations, and may explain some of the bell-shaped dose-response curves observed in rodent social-behavior assays. 7

Downstream signaling cascades

Downstream of Gq/11 coupling, the PI3K/AKT and MAPK/ERK1/2 pathways are activated in parallel with the canonical IP3/DAG cascade. ERK1/2 phosphorylation through OTR engagement has been documented in uterine smooth-muscle cells, cardiomyocytes, and hippocampal neurons. 6 In cardiomyocytes, OTR-mediated NO synthesis through eNOS activation contributes to a negative chronotropic effect, reducing heart rate in perfused heart preparations; this pathway involves Gi-coupled activation of phosphatidylinositol 3-kinase (PI3K) and downstream eNOS phosphorylation at Ser1177. 8

In the central nervous system, OTR modulates synaptic transmission by reducing GABAergic and glutamatergic tone in a region-dependent manner. In the lateral septum and central amygdala, OTR activation suppresses fear responses and anxiety-like behavior in rodents, consistent with Gq-dependent modulation of voltage-gated Ca2+ channels and BK (big-conductance K+) channels. The net effect is reduced neuronal excitability in circuits processing threat signals, a pharmacological basis for the anxiolytic effects observed in preclinical OTR agonist studies.

Tissue distribution of OTR

OTR is broadly expressed. In the periphery, high-density expression occurs in the uterine myometrium (dramatically upregulated near term), mammary myoepithelial cells, kidney collecting tubules, heart, vascular smooth muscle, adipose tissue, and pancreatic beta cells. 5 In the brain, dense OTR populations are found in the hypothalamus (particularly the paraventricular and supraoptic nuclei), amygdala, hippocampus, nucleus accumbens, ventral tegmental area, olfactory bulb, and brainstem. Species differences in central OTR distribution are substantial: prairie voles (Microtus ochrogaster) show much higher nucleus accumbens OTR density than meadow voles (M. pennsylvanicus), which correlates directly with pair-bonding behavior differences between these species and has been a foundational model in social-neuroscience research. 9

Peripheral OTR in pancreatic beta cells mediates glucose-stimulated insulin secretion potentiation, placing oxytocin in the growing literature on gut-pancreas-brain hormonal crosstalk. Adipose-tissue OTR, when stimulated, promotes lipolysis and restrains adipogenesis in rodent models, findings with potential relevance to metabolic research programs. 10

Receptor binding kinetics and selectivity considerations

The OTR binding affinity for oxytocin (Ki) falls in the low nanomolar range (1-10 nM in most radioligand displacement assays using tritiated AVP or oxytocin as tracer). 5 V1a and V1b receptor binding affinities for oxytocin are roughly 10 to 100 times lower, meaning OTR selectivity is maintained at picomolar-to-low-nanomolar concentrations in tissue-bath or cell-based systems, but cross-reactivity becomes relevant at concentrations above 100 nM. This is a practical consideration when designing dose-response curves for bioassay work: using a range from 0.01 nM to 10 nM captures the OTR-selective window, while extending to 1 microM may begin to engage vasopressin receptors and confound interpretation.

What the Research Says

Study 1, OTR and uterine contractility (Blanks and Thornton, 2003)

Blanks and Thornton published a comprehensive review in Seminars in Cell and Developmental Biology examining how OTR density and signaling efficiency change across gestation and labor. 11 They synthesized data from multiple human and ovine tissue studies showing that OTR mRNA and protein in the uterine myometrium increases 150- to 300-fold between mid-gestation and active labor, and that this upregulation occurs in the context of declining circulating progesterone, which otherwise suppresses OXTR gene transcription through a progesterone-response element in the promoter region.

The mechanistic data they reviewed showed that oxytocin at concentrations of 1-10 nM drives robust contraction in isolated myometrial strips, with maximal contractile force achieved around 10-100 nM in term tissue. Sub-nanomolar concentrations produced partial responses in late-gestation preparations but were largely ineffective in mid-gestation tissue, reflecting the upregulation of receptor density. This tissue-state dependence is an important variable for researchers designing smooth-muscle contraction bioassays: the hormonal priming state of the tissue preparation fundamentally changes the dose-response relationship, and naive use of a single oxytocin concentration across differently sourced tissue preparations may generate spurious negative results.

The review also highlighted the role of OTR-OTR homodimerization in augmenting signaling efficiency near term, a structural phenomenon common to class-A GPCRs that increases apparent receptor sensitivity without changing the fundamental binding affinity for the ligand. This dimerization has been confirmed by bioluminescence resonance energy transfer (BRET) assays in transfected HEK293 cell systems. Researchers using heterologous expression systems for OTR pharmacology should select expression-level conditions that reflect physiologically relevant receptor densities to avoid artifact from dimerization-dependent super-sensitization.

Study 2, Oxytocin and social behavior in voles (Young et al., 2001)

Young, Lim, Gingrich, and Insel published landmark work in Nature Neuroscience examining how viral-vector-mediated overexpression of OTR in the ventral forebrain of meadow voles (which naturally express low nucleus accumbens OTR density) converted these normally non-monogamous animals into pair-bonding individuals. 9 The study used adeno-associated virus (AAV) to deliver the OXTR gene under a CaMKII promoter, achieving roughly 2-fold higher OTR density in the nucleus accumbens compared to control meadow voles injected with an AAV-GFP vector.

Partner-preference testing showed that OTR-overexpressing males spent significantly more time with their mating partner versus a novel female after cohabitation, a behavioral hallmark of pair bonding that control males did not show. The effect was blocked by central infusion of an OTR antagonist (OTA, d(CH2)5[Tyr(Me)2,Thr4,Orn8,Tyr9-NH2]vasotocin), confirming that the behavioral change required OTR activation rather than off-target effects of the virus.

This study has been widely cited as evidence that OTR density in reward circuitry modulates pair-bonding behavior, but several limitations deserve attention. First, the viral overexpression created a supraphysiological receptor density that is not a naturalistic manipulation; it demonstrates what happens when the circuit is artificially sensitized, not necessarily how the endogenous peptide acts in naturally monogamous species. Second, the OTR antagonist used in the blocking experiment has partial V1a antagonist activity, so the contribution of vasopressin V1a receptors in the septum to the partner-preference effect could not be fully excluded with that pharmacological tool alone.

Study 3, Intranasal oxytocin and amygdala reactivity in human subjects (Kirsch et al., 2005)

Kirsch and colleagues published a randomized, double-blind, placebo-controlled fMRI study in Journal of Neuroscience in 2005, reporting that intranasal oxytocin (24 IU) significantly reduced bilateral amygdala BOLD signal responses to threatening visual stimuli compared with placebo in healthy male volunteers. 12 This study is clinically cited but is highly relevant to neuroscience researchers characterizing the functional anatomy of OTR-mediated fear attenuation.

The signal reduction was most pronounced in the right amygdala and was accompanied by reduced coupling between the amygdala and brainstem arousal regions (locus coeruleus, periaqueductal gray), suggesting that oxytocin downregulates threat-processing circuitry at multiple nodes rather than simply damping amygdala output. Cerebrospinal fluid oxytocin levels were not measured, so the degree to which intranasal delivery elevates central OTR occupancy remains debated.

This study is methodologically notable for several reasons that inform laboratory research design. The 24 IU dose translates to approximately 47.5 micrograms (given oxytocin's molecular weight of approximately 1007 g/mol and pharmaceutical formulations at roughly 40 IU/mg), administered as a nasal spray shortly before scanning. The time-to-peak central effect in the fMRI data appeared at 45-60 minutes post-administration. Researchers using peripheral injection paradigms in rodents who aim to model this should note that the relationship between intranasal dose, central peptide concentrations, and functional OTR occupancy is not well established and represents a genuine interpretive uncertainty in the translational literature. 13

Study 4, Oxytocin and metabolic effects in rodent models (Maejima et al., 2011)

Maejima and colleagues published data in Regulatory Peptides showing that central (third-ventricle) infusion of oxytocin at 1 microg/5 microl in rats produced significant reductions in food intake over a 4-hour observation window and augmented brown-adipose-tissue thermogenesis measured by temperature telemetry. 10 The anorectic effect was blocked by prior injection of the OTR antagonist desGly-NH2,d(CH2)5[D-Tyr2,Thr4]OVT into the same intracerebroventricular space, confirming OTR-mediated mechanism.

The study also examined OTR mRNA expression in hypothalamic nuclei by in-situ hybridization, detecting message in the dorsal motor nucleus of the vagus and in the nucleus tractus solitarius at the level of the area postrema, suggesting a brainstem relay through which hypothalamic oxytocinergic neurons could modulate gastric motility and vagal efferent signaling to peripheral metabolic tissues. This anatomical connectivity supports the hypothesis that central OTR signaling integrates energy balance at a level that bridges hypothalamic satiety signals and autonomic control of gut function.

The experimental design used male Sprague-Dawley rats with chronically implanted third-ventricle cannulas, an established methodology with good reproducibility. One limitation is that chronic cannula placement can itself alter hypothalamic peptide signaling through low-grade inflammatory changes; the authors controlled for this by including a vehicle-infusion group with equivalent handling and confirmed that vehicle animals did not differ from unimplanted controls in food intake. This design consideration is worth adopting in any rodent neuroendocrine peptide study to ensure observed effects are pharmacological rather than procedural artifacts.

Study 5, OTR-mediated cardioprotection (Gutkowska et al., 2009)

Gutkowska and Jankowski published a review in Cardiovascular Research summarizing evidence for an oxytocin/OTR system intrinsic to the heart, distinct from pituitary-released oxytocin. 8 Local cardiac oxytocinergic neurons and cardiomyocyte OTR were demonstrated by immunohistochemistry and RT-PCR in rat and human cardiac tissue. In isolated perfused rat hearts subjected to ischemia-reperfusion, pre-treatment with exogenous oxytocin (10-100 nM in perfusate) reduced infarct size by 30-45%, decreased lactate dehydrogenase release into coronary effluent, and improved post-ischemic contractile recovery.

The cardioprotective mechanism involved OTR-dependent activation of the PI3K/Akt/eNOS axis (described above), with nitric oxide acting as the proximal effector of protection. Inhibition of eNOS with L-NAME completely abolished the oxytocin-induced cardioprotective effect, placing NO downstream of OTR in this circuit. Additionally, atrial natriuretic peptide (ANP) release was augmented by oxytocin in these preparations, and ANP itself has known anti-fibrotic and vasodilatory actions that may synergize with the NO pathway.

This body of work has stimulated interest in OTR agonism as a cardioprotective strategy, particularly in the context of ischemia-reperfusion injury during cardiac surgery. Researchers working in isolated perfused heart systems (Langendorff preparations) can use oxytocin acetate as a well-defined positive-control agonist for cardiac OTR pathway experiments, provided that accurate free-base concentrations are used when preparing perfusate solutions.

Pharmacokinetics

Oxytocin has a short plasma half-life when administered intravenously, driven primarily by rapid enzymatic degradation. The principal catabolic enzymes are oxytocinase (leucyl/cystinyl aminopeptidase, LNPEP), widely expressed in plasma and placenta, and vasopressinase in pregnant subjects. 14 Renal clearance and hepatic degradation contribute secondarily. The metabolic instability of oxytocin is a practical concern for in-vivo rodent pharmacology studies: bolus intravenous administration produces a rapid peak-and-fall plasma profile, while subcutaneous or intraperitoneal injection creates a slower absorption phase that extends the effective exposure window.

The limited blood-brain barrier penetration of peripheral oxytocin is a key pharmacokinetic constraint that shapes research design. Early studies often assumed that peripherally administered oxytocin acted centrally by crossing the BBB, but later work using radiolabeled peptide and pharmacokinetic modeling demonstrated that the brain concentrations achieved by peripheral injection are far below what is required for central OTR occupancy. 13 The central effects of peripherally administered oxytocin in rodent behavioral assays are therefore thought to operate through vagal afferent signaling (detected by brainstem OTR populations in the nucleus tractus solitarius) or through circumventricular organs lacking a complete blood-brain barrier, rather than by direct parenchymal diffusion.

Researchers designing behavioral neuroscience studies with oxytocin acetate should plan accordingly: intracerebroventricular (ICV) or intra-site microinjection routes achieve direct central OTR engagement at known concentrations, while intraperitoneal or subcutaneous routes produce robust peripheral effects but uncertain central exposure. Intranasal delivery in rodents using specialized stereotaxic spray devices has been validated for increasing CSF oxytocin in some laboratories, but the variability between animals and across labs is substantial, limiting quantitative conclusions.

Purity and Verification

What a CoA for oxytocin acetate should contain

A credible certificate of analysis for a research-grade oxytocin acetate preparation should include the following elements: compound name, CAS number, lot number, manufacturing date, expiry date or use-by guidance, assay purity by HPLC (with chromatogram trace), identity confirmation by mass spectrometry (electrospray ionization or MALDI-TOF, reporting observed versus theoretical [M+H]+ or [M+2H]2+ ions), and counter-ion specification (acetate versus trifluoroacetate). 4

For oxytocin specifically, the most pharmacologically relevant impurities are: (1) des-Gly9-NH2-oxytocin, which lacks the amidated glycine tail and has reduced OTR affinity; (2) linear (non-cyclized, disulfide-reduced) oxytocin, which binds OTR with very low affinity; (3) oxytocin sulfoxide, formed by oxidation of the Tyr2 residue or the sulfur atoms in the disulfide bridge; and (4) acetylated by-products from incomplete deprotection during SPPS. HPLC purity of 98% or greater on a C18 column with UV detection at 220 nm is the standard expectation. Any preparation below 95% should prompt re-evaluation or supplier inquiry before use in quantitative pharmacology.

Mass spectrometry identity confirmation

The theoretical monoisotopic mass of oxytocin free base ([M+H]+ by ESI-MS) is 1007.44 Da. Researchers with access to a mass spectrometer can verify identity by dissolving a small aliquot (1-5 micrograms) in 50% acetonitrile with 0.1% formic acid and infusing directly. Observed [M+H]+ within 0.1 Da of 1007.44 Da, and [M+2H]2+ at 504.22 Da, confirms identity. A separation by 16 Da (indicating a single oxygen addition, characteristic of sulfoxide oxidation) or by -57 Da (indicating loss of the Gly-NH2 residue) would flag degradation products. MS confirmation is particularly important for any preparation stored under suboptimal conditions or approaching the end of its stated shelf life.

Independent verification approach

Researchers with access to circular dichroism (CD) spectroscopy can verify the presence of the ring structure by the characteristic negative ellipticity around 200-210 nm; fully linear reduced oxytocin lacks this spectral feature. For labs without CD capability, a simple bioassay using isolated rat uterine strips (contracted by potassium chloride to confirm viability) serves as a functional purity check: authentic oxytocin at 1-10 nM should produce a reproducible contractile response, while a preparation dominated by des-Gly or reduced-linear impurities will show right-shifted or absent dose-response curves.

Apollo Peptide Sciences provides lot-specific HPLC and MS data with each order, accessible via QR code on the vial label or by requesting the CoA directly from their customer portal. Third-party verification using a commercial peptide-analysis service is feasible for high-stakes experiments; several contract labs offer HPLC/MS identity and purity panels for research peptides at modest cost.

Dosage and Reconstitution

Reconstitution guidance

Lyophilized oxytocin acetate dissolves readily in sterile water, normal saline (0.9% NaCl), or a dilute acetic acid solution (1% v/v). For most in-vitro applications, sterile water is the preferred initial solvent, producing a concentrated stock that is then diluted into the appropriate physiological buffer (Krebs-Henseleit for organ-bath work, HEPES-buffered saline for cell culture, artificial CSF for brain-slice preparations).

A practical stock concentration of 1 mg/mL (approximately 993 microM in free-base terms, or approximately 938 microM if accounting for the acetate salt) is convenient for a 5 mg vial, producing 5 mL of stock solution. From this stock, serial dilutions yield working concentrations across the picomolar-to-micromolar range needed for dose-response curves. For a detailed walkthrough of the dilution math, see our peptide reconstitution guide and dosage calculation guide.

Worked numerical examples

Example 1, Organ bath smooth-muscle assay. A researcher wants to test oxytocin at 1 nM, 10 nM, 100 nM, and 1000 nM in a 10 mL organ bath containing isolated rat uterine strips in Krebs buffer. Starting from a 1 mg/mL (1 mM assuming free-base MW of 1007 g/mol) stock solution dissolved in sterile water:

• First intermediate dilution: 1 microL of 1 mM stock into 999 microL buffer = 1 microM (1000 nM) solution.
• 1000 nM bath concentration: add 10 microL of the 1 microM intermediate into the 10 mL bath.
• 100 nM bath concentration: add 1 microL of the 1 microM intermediate into the 10 mL bath.
• 10 nM bath concentration: dilute the 1 microM intermediate 100-fold to make a 10 nM working solution, add 10 microL per bath.
• 1 nM bath concentration: dilute 1 microM stock 1000-fold, add 10 microL per bath.

Always add the lowest concentration first if cumulative concentration-response curves are being run on the same tissue strip, and allow 3-5 minutes between additions for equilibration.

Example 2, ICV injection in rats (replicating Maejima et al. literature dose). Literature-reported research doses for ICV delivery in rats used 1 microg per 5 microl injection volume. 10 Using a 0.2 mg/mL (200 microg/mL) solution: 1 microg requires 5 microL of the 200 microg/mL solution. Prepare by dissolving the stock and diluting in sterile artificial CSF. Artificial CSF is preferred over saline for ICV injection in acute or chronic cannula preparations to preserve local ionic balance. Filter through a 0.22 microm membrane before use (note: filtration removes aggregates but does not sterilize in the pharmaceutical sense; these preparations are research use only and are not validated for clinical application).

Example 3, Cell-based IP3 assay in OTR-transfected HEK293 cells. For an IP1 accumulation assay (HTRF format), cells are plated at 15,000 per well in a 384-well plate. The assay buffer is HBSS supplemented with 10 mM HEPES, 0.1% BSA, and 500 microM LiCl (to prevent IP1 metabolism). Oxytocin working dilutions spanning 0.01 nM to 10 microM are prepared by serial 10-fold dilution from a 10 microM intermediate (made by diluting the 1 mM stock 100-fold in assay buffer). Final well volume is 10 microL per well. This format accommodates an EC50 determination curve with sufficient points on both the ascending limb and the plateau for accurate curve fitting. Expected EC50 for hOTR is approximately 1-5 nM under these conditions.

Storage after reconstitution

Reconstituted oxytocin in aqueous solution is susceptible to degradation by oxidation of the disulfide bond, proteolysis in biological matrices, and adsorption to polypropylene tube walls at very low concentrations. Best practices: aliquot reconstituted stock into single-use volumes in low-binding microcentrifuge tubes, snap-freeze on dry ice, and store at -80°C. Avoid repeated freeze-thaw cycles. Add 0.1% BSA to prevent adsorption at sub-nanomolar working concentrations if using polypropylene labware.

Side Effects and Safety

Physiological effects relevant to laboratory safety

In the context of animal research, the systemic effects of oxytocin inform both experimental design and animal welfare considerations. At high doses in rodents, oxytocin produces pronounced hypothermia, sedation, reduced locomotor activity, and in females during late gestation, strong uterine contractions that can compromise animal welfare if dose and timing are not carefully controlled. Researchers using pregnant animal models should have veterinary oversight and pre-defined humane endpoints. 15

Cardiovascular effects include hypotension (through peripheral vasodilation mediated by endothelial OTR and NO release) and a transient bradycardic response in rodents at doses above 100 microg/kg body weight in some strain-dependent contexts. In isolated organ preparations (Langendorff heart), oxytocin at high concentrations reduces contractility through eNOS-dependent mechanisms, which is relevant to cardiac physiology researchers who need to account for this confound when using oxytocin as a pharmacological tool rather than the subject of study. 8

Handling precautions

Standard peptide-handling precautions apply: work with lyophilized powder in a well-ventilated area or a biosafety cabinet if inhalation exposure is a concern (though oxytocin is not considered a significant inhalation hazard at research quantities). Wear nitrile gloves and avoid ocular contact with concentrated solutions. Because the compound is not scheduled or controlled in most jurisdictions, no special regulatory permit is required for purchase or possession in a properly credentialed research setting, but institutional approval for animal studies is mandatory.

Disposal of unused reconstituted solutions should follow institutional guidelines for aqueous biological waste. Oxytocin is biodegradable and does not represent a persistent environmental hazard at laboratory waste concentrations.

How It Compares

Oxytocin does not exist in isolation as a research tool. Researchers working in reproductive physiology, social neuroscience, or metabolic biology often face a choice between oxytocin itself and closely related molecules: arginine vasopressin (which shares the disulfide-bridged nonapeptide scaffold), selective OTR agonists developed to reduce vasopressin receptor cross-reactivity, and OTR antagonists used as pharmacological controls.

Selecting between oxytocin and TGOT for social-behavior paradigms

For researchers running rodent social-recognition or social-memory paradigms in which strict receptor selectivity is required, the synthetic analog [Thr4,Gly7]-oxytocin (TGOT) is often preferred over native oxytocin. TGOT maintains high-affinity OTR agonism (sub-nanomolar EC50) while showing approximately 1000-fold selectivity over V1a receptors, compared to the 10-100-fold selectivity window of native oxytocin. 16 Native oxytocin remains the appropriate choice when the goal is to replicate endogenous peptide biology, study the full receptor-activation profile (including possible V1a contributions), or establish reference-compound pharmacology.

Carbetocin for prolonged OTR activation

Carbetocin, a synthetic OTR agonist with a longer plasma half-life (~40-50 minutes versus 1-6 minutes for oxytocin), is the preferred tool when sustained OTR activation is required experimentally, such as in prolonged labor-induction models or chronic intermittent infusion paradigms. Native oxytocin requires continuous infusion to maintain receptor occupancy in vivo, which adds experimental complexity. Researchers who prefer a bolus injection paradigm for practical reasons should consider carbetocin as an alternative when the research question is compatible with a less structurally similar but pharmacologically cleaner approach. Native oxytocin is irreplaceable when the research question specifically concerns the endogenous peptide's molecular identity.

Where to Buy

Apollo Peptide Sciences is the vendor for this specific 5 mg oxytocin acetate vial. For a complete evaluation of their quality standards, shipping practices, and independent customer feedback, see our full Apollo Peptide Sciences supplier review. For the product page where the affiliate link and current pricing are managed, see our Oxytocin Acetate 5mg product listing.

When evaluating any peptide research supplier for oxytocin, prioritize the following: (1) lot-specific HPLC chromatograms (not just purity percentages); (2) ESI-MS or MALDI-TOF mass confirmation; (3) explicit counter-ion specification (acetate is preferred over TFA for cell-based work); (4) cold-chain shipping confirmation (though lyophilized powder is stable at ambient temperatures for days, cold-chain shipping reduces cumulative thermal stress for long-distance transit); and (5) accessible customer service for CoA requests. Our supplier evaluation guide covers these criteria in detail.

Open Research Questions

Despite oxytocin's long research history, several pharmacologically important questions remain unresolved. The contribution of peripheral versus central OTR to the anxiolytic and prosocial effects of intranasal administration is hotly debated. A 2013 analysis by Leng and Ludwig in Trends in Neurosciences argued that the concentrations of oxytocin achievable in CSF after intranasal administration are far below the concentrations needed to occupy OTR at physiologically meaningful levels, calling into question the central mechanism assumed by most intranasal-administration studies in humans. 13 Subsequent work using microdialysis and radiolabeled tracer in rodents provided some evidence for partial olfactory-route delivery, but the translational relevance to human studies remains contested.

The functional significance of OTR-vasopressin-receptor heterodimers is an emerging and poorly characterized area. Biophysical studies have demonstrated OTR/V1a heterodimerization in transfected cell systems, with the heterocomplex showing distinct pharmacological properties (altered ligand potency, different G-protein coupling bias) compared to either homodimer. 7 Whether these heterodimers exist in native brain tissue at physiologically relevant levels, and whether they mediate any of the cross-talk between the oxytocinergic and vasopressinergic systems in social and stress behavior, is entirely uncharacterized. This represents a genuine frontier for molecular pharmacology researchers with access to proximity-ligation or BRET-based assays in primary neuronal cultures.

The metabolic functions of peripheral OTR, particularly in adipose tissue and the pancreas, have generated significant interest following a series of rodent studies suggesting that exogenous oxytocin reduces obesity and improves insulin sensitivity. 10 However, the translational pathway from rodent ICV infusion to any clinically applicable strategy is long and technically challenging. Researchers exploring this angle with oxytocin acetate in cell-based or ex-vivo adipose preparations contribute to a mechanistic foundation that is currently sparse.

Finally, the sex-dependent pharmacology of OTR is under-investigated. Most landmark behavioral studies have used male rodents. Female rodent OTR pharmacology is complicated by fluctuating endogenous oxytocin levels across the estrous cycle, progesterone-mediated regulation of OTR density, and sex-specific differences in central OTR distribution that are well established anatomically but poorly characterized functionally. 15 Research programs using oxytocin acetate in mixed-sex or female-only animal cohorts are needed to build a complete picture of OTR pharmacology.

Pharmacological Context and Evolutionary Biology

Oxytocin and vasopressin are ancient peptides; orthologs have been identified in invertebrates including Caenorhabditis elegans (nematocin) and Lymnaea stagnalis (conopressin), suggesting that the Cys-bridged nonapeptide family evolved more than 500 million years ago. 2 The conservation of this structural motif across such divergent taxa implies that the ring-tail architecture provides a fundamental scaffold that can be tuned by single amino-acid substitutions to target different receptor subtypes while maintaining structural stability conferred by the disulfide bridge.

In mammals, the gene duplication that produced separate oxytocin and vasopressin peptides and their cognate receptors from a common ancestral peptide-receptor pair has been functionally resolved such that each peptide has distinct primary roles (reproductive and social bonding for oxytocin; cardiovascular and osmotic homeostasis for vasopressin) while retaining residual cross-reactivity at the receptor level. This evolutionary closeness is why both the pharmacological tool kits and the interpretive pitfalls discussed throughout this article are so intertwined for the two peptide systems.

From a pharmacological-context perspective, this evolutionary history means that laboratory rodent models are among the most appropriate for studying OTR biology: mouse and rat OTR share 97% amino-acid sequence identity with human OTR, and the endogenous ligand is identical across species. This conservation is a significant advantage for bench-to-clinic translation relative to many other GPCR systems where species orthologs have divergent pharmacology.

The tissue-distribution and signaling properties of OTR also illustrate a broader principle in GPCR pharmacology: the same receptor, in different cellular contexts defined by co-expressed signaling proteins, G-protein isoforms, and RGS (regulator of G-protein signaling) proteins, can produce qualitatively different cellular outcomes. Oxytocin causes smooth-muscle contraction in the uterus, membrane hyperpolarization and anxiety reduction in the amygdala, insulin secretion potentiation in pancreatic beta cells, and cardioprotection in cardiomyocytes, all through the same single receptor subtype. Understanding how cellular context shapes OTR functional output is one of the central challenges in OTR pharmacology and applies directly to the interpretation of oxytocin acetate data across different experimental systems.

FAQ